8-K: Nu Skin Enterprises Reports Q1 2025 Revenue at High End of Guidance, Exceeds Adjusted Earnings Forecast

Nu Skin Enterprises announced first quarter revenue at the high end of its guidance range, with revenue reaching $364.5 million.

Summary

• Nu Skin Enterprises reported Q1 2025 revenue of $364.5 million, a 12.7% decrease year-over-year, but at the high end of their guidance.
• Excluding a 3.0% foreign exchange impact, the revenue decrease was 9.7%.
• Earnings per share (EPS) was $2.14, or $0.23 excluding the Mavely gain and other charges.
• This compares to $(0.01) or $0.09 excluding restructuring charges in the prior year.
• The company's customer base decreased by 11% to 776,712, while paid affiliates decreased by 15% to 131,518, and sales leaders decreased by 20% to 31,036.
• Gross margin was 67.8% compared to 70.5% in the prior year.
• The company reported a $176.2 million gain on the sale of its Mavely business.
• Nu Skin is maintaining its adjusted annual guidance and projects Q2 2025 revenue between $355 million and $390 million, with EPS in the range of $0.20 to $0.30.
• The company forecasts 2025 revenue between $1.48 and $1.62 billion and EPS between $2.80 and $3.20, or $0.90 to $1.30 excluding the Mavely gain and other charges.
• The company reduced outstanding debt by $155 million, achieving the lowest debt level in more than 10 years.
• The company returned $8 million to shareholders through dividends and share repurchases.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down year-over-year, the company met its revenue guidance and exceeded earnings expectations. Debt reduction and shareholder returns are positive signs, but macroeconomic uncertainties and declining customer numbers temper the outlook.

Positives

• Nu Skin achieved revenue at the high end of its guidance range.
• The company exceeded its adjusted earnings forecast.
• Nu Skin experienced year-over-year growth in Latin America and its Rhyz manufacturing segment.
• The company saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost efficiency initiatives.
• Nu Skin made meaningful progress in strengthening its balance sheet by reducing outstanding debt by $155 million.
• The company returned $8 million to shareholders through dividends and share repurchases.
• The company reported a $176.2 million gain on the sale of its Mavely business.

Negatives

• Overall revenue decreased by 12.7% year-over-year.
• The company experienced consumer caution in premium beauty due to concerns such as inflation and tariffs.
• The customer base decreased by 11% to 776,712.
• Paid affiliates decreased by 15% to 131,518.
• Sales leaders decreased by 20% to 31,036.
• Gross margin decreased to 67.8% compared to 70.5% in the prior year.
• The company experienced revenue declines in most regions, including Mainland China, Europe & Africa, and South Korea.

Risks

• Macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility.
• Any failure of current or planned initiatives or products to generate interest among the company's sales force and customers.
• Risk that direct selling laws and regulations may be modified, interpreted, or enforced in a manner that negatively impacts the company's business model.
• Economic conditions and events globally could negatively impact the company's business.
• Adverse publicity related to the company's business, products, or industry could negatively impact the company's business.
• Political, legal, tax, and regulatory uncertainties associated with operating in Mainland China and other international markets could negatively impact the company's business.
• Uncertainties regarding the future financial performance of the businesses the company has acquired could negatively impact the company's business.
• Risks related to accurately predicting, delivering, or maintaining sufficient quantities of products to support planned initiatives or launch strategies could negatively impact the company's business.
• Regulatory risks associated with the company's products could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market.

Future Outlook

Nu Skin projects Q2 2025 revenue between $355 million and $390 million, with earnings per share in the range of $0.20 to $0.30. The company forecasts 2025 revenue between $1.48 and $1.62 billion and EPS between $2.80 and $3.20, or $0.90 to $1.30 excluding the Mavely gain and other charges.

Management Comments

• We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year, said Ryan Napierski, Nu Skin president and CEO.
• Through 2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year.
• We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our efforts to continue improving margins across the board.
• In addition to delivering on revenue and adjusted earnings, we saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost efficiency initiatives across every segment, said James D. Thomas, chief financial officer.
• While macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility, we are maintaining our adjusted annual guidance as we closely monitor developments throughout the remainder of 2025.

Industry Context

Nu Skin operates in the competitive beauty and wellness industry, facing challenges such as consumer caution due to inflation and tariffs. The company is focusing on product innovation, geographic expansion, and cost efficiency to drive growth and improve margins. The launch of the Prysm iO device and expansion into India are key strategic initiatives.

Comparison to Industry Standards

• Direct selling companies like Herbalife Nutrition and Avon Products often face similar challenges related to sales force management and regulatory scrutiny.
• Nu Skin's focus on beauty devices aligns with trends seen at companies like L'Oréal and Estée Lauder, which have also invested in technology-driven beauty solutions.
• The expansion into India mirrors strategies employed by many multinational corporations seeking growth in emerging markets.
• Nu Skin's gross margin of 67.8% is comparable to other premium beauty companies, but lower than some luxury brands with higher pricing power.
• The company's debt reduction efforts are a positive sign, as many companies in the consumer discretionary sector are focused on strengthening their balance sheets.

Stakeholder Impact

• Shareholders will benefit from the dividend payments and share repurchases.
• Employees may be impacted by ongoing cost efficiency initiatives.
• Customers will have access to new products and technologies, such as the Prysm iO device.
• Suppliers may be affected by changes in product demand and supply chain optimization.
• Creditors will benefit from the company's debt reduction efforts.

Next Steps

• Build on recent product launches.
• Prepare for the preview of the Prysm iO intelligent wellness device in the back half of 2025.
• Continue laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026.
• Prioritize efforts to continue improving margins across the board.
• Closely monitor macroeconomic developments throughout the remainder of 2025.

Key Dates

Keywords

Nu Skin, Revenue, Earnings, Financial Results, Q1 2025, Guidance, Mavely, Rhyz, Beauty, Wellness